Unicycive Therapeutics’ $130 Million Private Placement

Sheppard Mullin advised Unicycive Therapeutics on the deal.Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease,…